What Is It?
A small molecule peptide from Washington State University, designed to cross the blood-brain barrier for Alzheimer's research. Went viral with the claim of being "7 orders of magnitude more potent than BDNF."
How Does It Work?
The key paper was retracted in 2021 for image manipulation in Western blot data. The viral potency claim is now unsupported. Earlier rodent studies remain intact, but the headline number that drove Dihexa's popularity no longer has a verified foundation. This is a lesson in how hype outlives data.
Primary Benefits (research suggests)
- Earlier rodent studies showed cognitive enhancement potential
- The compound crosses the blood-brain barrier
Run the Numbers
Calculate your Dihexa dosing — capsule strength, daily totals, and protocol planning. Free, no login required.
Open the Calculator →The Honest Part
- KEY PAPER RETRACTED in 2021 for image manipulation.
- The "7 orders of magnitude more potent than BDNF" claim is unsupported.
- Zero human trials.
- Zero FDA approval.
- Most vendors still cite the retracted study.
- This compound is included in the PMP library specifically as a case study in critical evaluation — not as a recommendation.
- For research purposes only.
Research Sources
Verified vendors offering this compound for research purposes. Use the vendor-specific code shown on each card for discounts. We may earn commissions from these links.
Track Dihexa in the App
Peptide Manager Pro tracks 100+ compounds with an interactive knowledge graph, dosing calculator, protocol tracker, and AI research chat. Veteran-owned. $4.99/mo founding rate.
Get the App →